Evidence map›Paper›PMID 39456874›Full record

ArticleInternational journal of molecular sciences2024

Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia.

Kana Kusaba, Tatsuro Watanabe, Keisuke Kidoguchi, Yuta Yamamoto, Ayaka Tomoda, Toshimi Hoshiko, Naoto Kojima, Susumu Nakata, Shinya Kimura

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kana KusabaDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan.
Tatsuro WatanabeDepartment of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga 849-8501, Japan.
Keisuke KidoguchiDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan.
Yuta YamamotoDepartment of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga 849-8501, Japan.
Ayaka TomodaDepartment of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga 849-8501, Japan.
Toshimi HoshikoClinical Research Center, Saga Medical School Hospital, Saga 849-8501, Japan.
Naoto KojimaFaculty of Pharmaceutical Sciences, Nagasaki International University, Nagasaki 859-3298, Japan.ORCID 0000-0002-4544-4583
Susumu NakataLaboratory of Clinical Oncology, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.
Shinya KimuraDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan.

Funding

Bristol-Myers-Squibb NAOhara Pharmaceuticals NAPfizer NA
6 · The paper itself

Abstract

Patients with chronic myeloid leukemia (CML) respond to tyrosine kinase inhibitors (TKIs); however, CML leukemic stem cells (LSCs) exhibit BCR::ABL kinase-independent growth and are insensitive to TKIs, leading to disease relapse. To prevent this, new therapies targeting CML-LSCs are needed. Rates of mitochondria-mediated oxidative phosphorylation (OXPHOS) in CD34

Indexed as

Imatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveNeoplastic Stem CellsOxidative PhosphorylationAnimalsAntineoplastic AgentsCell Line, TumorCell ProliferationDrug SynergismHumansMiceProtein Kinase InhibitorsThiophenesXenograft Model Antitumor AssaysAntineoplastic AgentsImatinib MesylateProtein Kinase InhibitorsThiopheneschronic myeloid leukemiaoxidative phosphorylationstem cellthiophene carboxamidetyrosine kinase

Identifiers

PMID39456874
PMCPMC11508009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.